Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.
Tortuga Growth Partners Invests in Advanced eClinical Training to Accelerate Healthcare Workforce Development
Investment Extends TGP’s Healthcare Platform and Positions Advanced eClinical Training to Meet Growing Demand for Patient-Centric Clinical Professionals
Tortuga Growth Partners (TGP), a New York-based private investment firm focused on building market leaders through disciplined buy-and-build strategies, today announced a strategic investment, made through Tortuga Growth Partners Fund I, L.P., in Advanced eClinical Training (ACT), one of the nation’s leading providers of online healthcare certification and workforce development. The investment extends TGP’s build-out of its healthcare vertical and underscores the firm’s conviction that scalable, technology-enabled solutions can address the clinical workforce shortage facing the U.S. healthcare system.
According to the American Hospital Association, the healthcare worker shortage in the US is projected to grow to over 3.2 million this year. ACT addresses the shortage of skilled clinical professionals through high-quality training, certification, and workforce readiness programs designed for the next generation of healthcare professionals. Since its founding in 2020, ACT has trained and certified over 10,000 healthcare professionals, placing them in critical frontline healthcare roles.
Founded by Shay Safarzadeh and Shabnam Safarzadeh, ACT has developed a clinical ecosystem of more than 1,000 healthcare partners, including urgent care centers, physician practices, outpatient clinics, diagnostic laboratories, and health systems nationwide. The company is recognized by Forbes as the #1 Certified Clinical Medical Assistant (CCMA) online certification program in the United States, with a 98% NHA exam pass rate.
“We built ACT to help address the growing demand for high-quality clinical workforce training,” said Shay Safarzadeh, Co-Founder. “Partnering with TGP gives us the strategic resources and shared conviction needed to accelerate our next phase of growth and continue building the market leader in healthcare workforce development.”
“TGP shares our vision for building an enduring platform in this category,” added Shabnam Safarzadeh, Co-Founder…
Full release here, originally announced August 4th, 2026.
QuantHealth Raises $45 Million Series B, led by Qumra Capital, to Accelerate Simulation-First Clinical Trial Development
Funding Will Advance QuantHealth’s R&D, Product Innovation, and Commercial Expansion Following 8x Sales Growth in 2025
QuantHealth, a global leader in AI-driven clinical trial simulation, today announced a $45 million Series B. The round was led by Qumra Capital, with support from additional investors, including Pitango HealthTech, Sanofi Ventures, Artofin Venture Capital Fund L.P., Bertelsmann Healthcare Investments (BHI), GC Ventures, NewHealth Ventures, Shoni Top Ventures, and Esplanade Ventures.
Building on strong momentum and growing adoption of its solutions, QuantHealth will use the new capital to scale its enterprise-wide impact and accelerate adoption of simulation-first clinical development. With this approach, life sciences organizations move away from designing clinical trials based on historical benchmarks and subjective assumptions, and toward launching trials that have been tested, optimized, and de-risked through AI-driven simulation before a patient is enrolled or capital is deployed.
Key investments include:
- Advancing its R&D capabilities with next-generation AI models, deeper scientific validation, expanded data sets, and increased therapeutic coverage
- Growing its workforce to support increasing industry demand and deliver expert-driven client engagements
- Expanding its product portfolio across the clinical and commercial lifecycle, from trial design through go-to-market positioning, with a focus on demonstrating measurable impact
Clinical trials remain one of the most costly and uncertain phases of drug development, with more than 90% of drugs that enter clinical development ultimately failing, approximately 75% due to efficacy and safety. As pressure mounts to bring therapies to market faster, while still ensuring safety and efficacy, pharmaceutical and biotech companies are increasingly turning to predictive technologies to guide decision-making…
Full release here, originally announced August 4th, 2026.
No comments:
Post a Comment